狂犬病疫联合干扰素的应用研究

目的 研究ＩＦＮ＋２－２－１程序和２－２－１程序应用的可行性,探讨ＩＦＮ的免疫调节作用。方法 ＩＦＮ＋２－２－１程序;于０、７、１４天分别注射５．０、５．０、２．５ＩＵ ＰＨＫＣＶ,于０天同时加注２０万ＩＵα－ＩＦＮ;２－２－１程序;于０、７、１４天分别注射５．０、５．０、２．５ＩＵＰＨＫＣＶ;对照：应用ＷＨＯ推荐的常规程序。结果 ①３种程序免疫后的ＧＭＴ;７天时分别为１．７１、１．５７、１．２１     

白念珠菌厚膜孢子形态发生过程的扫描电镜观察

目的 用扫描电镜观察白念珠菌厚膜孢子在液体培养基中形态发生过程。方法 用改良液体培养基培养白念珠菌厚膜孢子，在不同培养时间收获离心，制备扫描电镜样品，然后观察不同培养时相厚膜孢子及假菌丝的形态。结果 发现培养３小时芽生孢子发芽。５小时芽体延长；７小时次极芽体伸长，假菌丝形成，顶端孢子开始增大；９小时假菌丝延长，厚膜孢子进一步成熟；１６小时厚膜孢子成熟；２４小时见多数厚膜孢子和假菌。结论 用该方法能     

ON THE USE OF A NEW SOMATOSTATIN ANALOGUE IN THE TREATMENT OF HYPOGLYCAEMIA IN PATIENTS WITH INSULINOMA

A novel potent analogue of somatostatin, the octapepide SMS 201-995 was tested as a therapeutic manoeuvre to prevent hypoglycaemia in patients with insulinoma. We investigated the acute effects of a single 50 micrograms dose of the analogue administered s.c. in three patients, comparing the results in two of them with those obtained after administration of saline (control) and native somatostatin. In addition two patients were treated for up to 5 d with two or three daily s.c. injections (daily dose of analogue ranging from 100 to 300 micrograms). In two of the three patients SMS 201-995 suppressed circulating insulin levels by more than 50% and increased plasma glucose to hyperglycaemic levels for 6-8 h after a single injection. No undesirable effects of the administration of the analogue were observed. As opposed to insulin suppression obtained with native somatostatin, no rebound increase in insulin levels was observed after administration of the analogue. We conclude that SMS 201-995 prevented hypoglycaemia in two out of three patients with insulinoma. The advantage of s.c. administration, the long duration of action and the absence of a rebound phenomenon give this analogue a place in the pre-operative management of patients with insulinoma.     

THE USE OF AN LHRH AGONIST, BUSERELIN, IN THE LONG-TERM MANAGEMENT OF PREMENSTRUAL SYNDROMES

Buserelin, an LHRH agonist, was given by nasal spray to 20 women with premenstrual syndrome. In 10 women benefits were such that they continued treatment for periods varying from 5 to 15 months. There were significant improvements in mood and physical symptoms, and side-effects such as hot flushes were mild. The remaining 10 women were all made worse by the spray and stopped it within 2 months. Ovulation was blocked in all women though six showed evidence of ovulation during the first treatment month, and two women later in treatment. Of the long-term group, six eventually became amenorrhoeic, and four continued to menstruate. There was a significant improvement in symptoms during treatment in the long-term group. Physical symptoms continued to be worse before any menstrual bleeding. Mood change lost its relationship to menstruation. The adverse effects in the short-term group were sometimes severe and it is necessary to identify the characteristics of the woman who are likely to show such reactions before recommending this treatment for more general use.